Injection site reactions after dupilumab or tralokinumab for atopic dermatitis

Abstract

Background: Injection site reaction (ISR) is a local phenomenon defined as a constellation of symptoms, including swelling, erythema, pruritus, and pain around the site of injection.

Objective: ISR is reported as a frequent adverse event after subcutaneous injection (SCI) of several biologics.

Methods: We performed an observational real-life study to compare dupilumab and tralokinumab as regards ISR, analysing frequency, duration and intensity of symptoms related to SCI. From January 2023 to June 2023, we enrolled adult patients affected by moderate to severe AD and being on dupilumab or tralokinumab treatment. A 12 items questionnaire was administered to all enrolled patients.

Results and conclusions: Three hundred and ninety-two patients were included. ISR was a frequent occurrence in both the treatment groups, with tralokinumab causing ISR more frequently than dupilumab. However, the reactions were generally mild and no patient stopped therapy.

Keywords:

• Atopic dermatitis
• tralokinumab
• dupilumab

Disclosure statement

No potential conflict of interest was reported by the author(s).

Informed consent

The patients in this manuscript have given written informed consent to publication of their case details.

All authors read and approved the final version of the manuscript.

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.